Voxzogo

Voxzogo (vosoritide) is a prescription medicine used to treat achondroplasia in pediatric patients aged 5 years and older. It works by targeting the underlying cause of bone growth limitation. This injectable therapy is administered subcutaneously.

Voxzogo is prescribed to increase linear growth in children with achondroplasia, a genetic condition affecting bone development. It is designed for pediatric patients whose growth plates have not yet closed. The medication helps address the short stature associated with this condition by promoting bone growth.

Voxzogo may help improve annual growth velocity in eligible pediatric patients. Patients may notice gradual changes in height over time with consistent use. Common effects include injection site reactions, which are typically mild and temporary.

Voxzogo should only be administered by a healthcare professional or under their supervision. Patients or caregivers must follow proper injection techniques and disposal methods. Regular monitoring by a doctor is recommended to assess growth and potential side effects.

Limited data exists on drug interactions with vosoritide. Caution is advised when combining with other medications, especially those affecting bone metabolism. Patients should inform their healthcare provider about all medications, supplements, or herbal products they are using.